Literature DB >> 26649829

Topical Ruxolitinib for the Treatment of Alopecia Universalis.

Brittany G Craiglow1, Daniel Tavares2, Brett A King1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26649829     DOI： 10.1001/jamadermatol.2015.4445

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN： 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  21 in total

Review 1.  Vitiligo Pathogenesis and Emerging Treatments.

Authors:  Mehdi Rashighi; John E Harris
Journal:  Dermatol Clin       Date:  2017-04       Impact factor: 3.478

Review 2.  T-cell positioning by chemokines in autoimmune skin diseases.

Authors:  Jillian M Richmond; James P Strassner; Kingsley I Essien; John E Harris
Journal:  Immunol Rev       Date:  2019-05       Impact factor: 12.988

Review 3.  JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

Authors:  Daniella M Schwartz; Yuka Kanno; Alejandro Villarino; Michael Ward; Massimo Gadina; John J O'Shea
Journal:  Nat Rev Drug Discov       Date:  2017-11-06       Impact factor: 84.694

4.  JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

Authors:  Daniella M Schwartz; Yuka Kanno; Alejandro Villarino; Michael Ward; Massimo Gadina; John J O'Shea
Journal:  Nat Rev Drug Discov       Date:  2017-12-28       Impact factor: 84.694

Review 5.  JAK inhibitors in dermatology: The promise of a new drug class.

Authors:  William Damsky; Brett A King
Journal:  J Am Acad Dermatol       Date:  2017-01-28       Impact factor: 11.527

Review 6.  Pediatric Dermatology.

Authors:  Leslie Castelo-Soccio; Patrick McMahon
Journal:  J Clin Aesthet Dermatol       Date:  2017-03-01

Review 7.  Alopecia Areata: An Update on Treatment Options for Children.

Authors:  Lauren Peloquin; Leslie Castelo-Soccio
Journal:  Paediatr Drugs       Date:  2017-10       Impact factor: 3.022

8.  A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata.

Authors:  Daniela Mikhaylov; Jacob W Glickman; Ester Del Duca; John Nia; Peter Hashim; Giselle K Singer; Alba L Posligua; Aleksandra G Florek; Erin Ibler; Erika L Hagstrom; Yeriel Estrada; Stephanie M Rangel; Maria Colavincenzo; Amy S Paller; Emma Guttman-Yassky
Journal:  Arch Dermatol Res       Date:  2022-03-01       Impact factor: 3.017

Review 9.  Understanding autoimmunity of vitiligo and alopecia areata.

Authors:  Jillian F Rork; Mehdi Rashighi; John E Harris
Journal:  Curr Opin Pediatr       Date:  2016-08       Impact factor: 2.856

Review 10.  Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases.

Authors:  Massimo Gadina; Nathalia Gazaniga; Laura Vian; Yasuko Furumoto
Journal:  J Autoimmun       Date:  2017-07-01       Impact factor: 7.094
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.